NCT02000947 (D4190C00006) is a Phase 1 clinical trial of MEDI4736 in NSCLC, sponsored by MedImmune LLC.

Who is sponsoring NCT02000947?

NCT02000947 is sponsored by MedImmune LLC.

What drugs are being tested in NCT02000947?

Interventions in NCT02000947: MEDI4736, Tremelimumab, tremelimumab.

What condition does NCT02000947 study?

NCT02000947 studies NSCLC, Non-small Cell Lung Cancer, Lung Cancer.

Is NCT02000947 still recruiting?

NCT02000947 is currently completed. Last updated 31 October 2019.

Last reviewed 2019-10-31 · How we verify

NCT02000947: D4190C00006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Completed Phase 1 Last updated 31 October 2019

What this trial tests

Phase 1 trial testing MEDI4736 in NSCLC in 459 participants. Completed in 17 September 2019.

Timeline

25 October 2013

Primary endpoint
17 September 2019

17 September 2019

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	459
Start date	25 October 2013
Primary completion	17 September 2019
Estimated completion	17 September 2019
Sites	69 locations across France, Italy, Belgium, Taiwan, United Kingdom, South Korea, Australia, United States

Drugs / interventions tested

MEDI4736 — full drug profile →
Tremelimumab (TREMELIMUMAB) — full drug profile →
tremelimumab (TREMELIMUMAB) — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

MedImmune LLC — full company profile →

Who can join

Adults 18 to 101, any sex, with NSCLC or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A. · · 2019 · cited 708× · PMID 31196207 · DOI 10.1186/s13046-019-1259-z
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, et al · · 2016 · cited 500× · PMID 26858122 · DOI 10.1016/s1470-2045(15)00544-6
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Wu M, Huang Q, Xie Y, Wu X, et al · · 2022 · cited 336× · PMID 35279217 · DOI 10.1186/s13045-022-01242-2
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK, Arya A, Iams W, Cruz MR, et al · · 2018 · cited 336× · PMID 29769148 · DOI 10.1186/s40425-018-0349-3
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W, Gilligan BM, Yuan J, Li T. · · 2016 · cited 243× · PMID 27234522 · DOI 10.1186/s13045-016-0277-y
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.
Remark R, Becker C, Gomez JE, Damotte D, et al · · 2015 · cited 209× · PMID 25369536 · DOI 10.1164/rccm.201409-1671pp
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Memon D, Schoenfeld AJ, Ye D, Fromm G, et al · · 2024 · cited 150× · PMID 38215748 · DOI 10.1016/j.ccell.2023.12.013
Molecular pathways and therapeutic targets in lung cancer.
Shtivelman E, Hensing T, Simon GR, Dennis PA, et al · · 2014 · cited 150× · PMID 24722523 · DOI 10.18632/oncotarget.1891

Verify or expand the search:

Other trials of MEDI4736

Trials testing the same drug.

NCT02546661 — Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting
NCT02669914 — MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors · Phase 2 · terminated
NCT02868632 — Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer · Phase 1 · withdrawn
NCT02549651 — MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C0 · Phase 1 · completed
NCT02592551 — MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma · Phase 2 · completed

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other MedImmune LLC trials

Trials by the same sponsor.

NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02000947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
Last refreshed: 31 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02000947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing